<DOC>
	<DOCNO>NCT01219348</DOCNO>
	<brief_summary>Title : IDO peptid vaccination combination immune stimulate agent Aldara adjuvant Montanide , treatment patient locally advance metastatic non small-cell lung cancer . A first-in-man phase I trial . Hypothesis : In trial investigator assess new immunotherapeutic strategy target immune inhibiting enzyme , IDO investigate potential vaccination IDO possible anticancer target .</brief_summary>
	<brief_title>IDO Peptid Vaccination Stage III-IV Non Small-cell Lung Cancer Patients .</brief_title>
	<detailed_description>Background : Non small-cell lung cancer ( NSCLC ) common disease poor prognosis locally advance metastasize , despite advance surgery , chemo- radiation therapy . In trial investigator assess new immunotherapeutic strategy target immune inhibiting enzyme , IDO investigate potential vaccination IDO possible anticancer target . IDO recently recognize important factor immune regulation development immune tolerance microenvironment cancer cell . Cells represent IDO surface know inhibit immune system . IDO expression see cancer cell antigen present cell . The vaccination IDO express cell therefore two-sided . The vaccination therapy think block development immune tolerance induce IDO express cell . At time investigator aim stimulate production IDO specific T-cells , hence facilitate elimination IDO positive tumour cell . The primary end point safety toxicity evaluation . Secondary end point immunological clinical response .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Histological cytological verify non small cell lung cancer 2 . Metastatic locally advance incurable stage IIIIV NSCLC 3 . Patients need chemotherapy treatment 4 . Evaluable disease accord RECIST V. 1,1 criterion 5 . Patients must HLAA2 positive 6 . Patients &gt; 18 year old 7 . Performance status 01 8 . Life expectancy &gt; 3 month 9 . Acceptable bone marrow function , define . White blood cell count &gt; 2,5 * 109 /l b. Neutrophil count &gt; 1,5 * 109 /l c. Platelet count &gt; 75 * 109/l 10 . Creatinin measure &lt; 2,5 * upper limit value 11 . Acceptable liver function , define 1 . ASAT &lt; 100 U/L 2 . Bilirubin &lt; 30 U/L 12 . Women childbearing potential must control shcg inclusion 13 . Patients must provide write informed concent inclusion 13 . Termination chemotherapy treatment &gt; 28 day inclusion 14 . Termination radiotherapy treatment &gt; 28 day inclusion 15 . Inclusion least &gt; 4 week complicate gastric surgery 1 . Other malignancy except nonmelanoma skin cancer previous 5 year study inclusion 2 . Brain metastasis allow radical excision , patient least 1 month afterwards clinical radiographic progression 3 . Patients active gastric ulcer disease ; patient take antacid treatment include . 4 . Severe medical condition , severe asthma , severe COLD , severe arteriosclerosis diabetic disease 5 . Acute chronic infection ( ie . HIV , hepatitis , tuberculosis ) 6 . Severe allergic reaction previous anaphylactic shock 7 . Autoimmune diseases ( ie . autoimmune neutropenia/thrombopenia , hæmolytic anaemia , systemic lupus erythematosis , Sjøgrens disease , sclerodermia , Goodpastures syndrome , Addisons disease , active Graves disease ) 8 . Pregnant lactate woman 9 . Psychiatric disease , influence compliance 10 . Known hypersensitivity towards adjuvance Montanide , Aldara creme , adhesive tape . 11 . Treatment immunosuppressive therapy ( ie . dexamethasone , methotrexate ) 12 . Treatment experimental therapy 13 . Treatment anticancer therapy , except treatment osteoporosis 14 . No systemic chemotherapy , immunotherapy radiation therapy ( except locally ) allow 28 day inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>IDO enzyme</keyword>
	<keyword>Vaccination trial</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>NSCLC , stage III_IV</keyword>
	<keyword>Indeolamine 2,3 dioxygenase = IDO</keyword>
</DOC>